UCMYM802
/ UTC Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 13, 2024
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: UTC Therapeutics Inc.
New P1 trial • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Mesothelioma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1